Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia not Adequately Controlled with Current Lipid-Lowering Therapy: Design and Rationale of the ODYSSEY FH Studies
Crossref DOI link: https://doi.org/10.1007/s10557-014-6523-z
Published Online: 2014-05-20
Published Print: 2014-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kastelein, John J. P.
Robinson, Jennifer G.
Farnier, Michel
Krempf, Michel
Langslet, Gisle
Lorenzato, Christelle
Gipe, Daniel A.
Baccara-Dinet, Marie T.
License valid from 2014-05-20